Comprehensive Addiction and Recovery Act of 2016 (CARA) / Medicare Prescription Drug Benefit Program (CMS-10141)

ICR 201712-0938-003

OMB: 0938-0964

Federal Form Document

Forms and Documents
ICR Details
0938-0964 201712-0938-003
Historical Inactive 201506-0938-007
HHS/CMS CM-CPC
Comprehensive Addiction and Recovery Act of 2016 (CARA) / Medicare Prescription Drug Benefit Program (CMS-10141)
Revision of a currently approved collection   No
Regular
Comment filed on proposed rule and continue 01/29/2018
Retrieve Notice of Action (NOA) 12/26/2017
OMB files this comment in accordance with 5 CFR 1320.11( c ). This OMB action is not an approval to conduct or sponsor an information collection under the Paperwork Reduction Act of 1995. This action has no effect on any current approvals. If OMB has assigned this ICR a new OMB Control Number, the OMB Control Number will not appear in the active inventory. For future submissions of this information collection, reference the OMB Control Number provided. OMB is withholding approval at this time. Prior to publication of the final rule, the agency should provide a summary of any comments related to the information collection and their response, including any changes made to the ICR.
  Inventory as of this Action Requested Previously Approved
10/31/2018 36 Months From Approved 11/30/2018
46,099,944 0 46,099,944
7,588,143 0 7,588,143
0 0 0

Part D plans and, to the extent applicable, MA organizations will use the information discussed below to comply with the eligibility and other requirements associated with their participation in Part D. CMS will use this information from plan sponsors and States to approve contract applications, monitor compliance with contract requirements, make proper payment to plans, and ensure that correct information is disclosed to potential and current enrollees. The new information collection will allow CMS to ensure sponsors have plans in place to restore business operations following a disruption of regular operations. Medicare beneficiaries will use the information provided by the Part D sponsors to make decisions regarding Part D enrollment as well as grievance and appeal requests. Under CMS-4182-P (RIN 0938-AT08), CMS will make the Preclusion List available to Part D sponsors. The Part D sponsors will perform system programming to maintain the Preclusion List in order to reject a pharmacy claim (or deny a beneficiary request for reimbursement) for a Part D drug that is prescribed by an individual on the Preclusion List. CMS will create and disseminate model notices to the prescribers to notify them of their existence on the Preclusion List, while the Part D sponsors will create and disseminate model notices to the Medicare beneficiaries to notify them that the pharmacy claim is being rejected or denied due to the prescriber’s existence on the Preclusion List.

Statute at Large: 18 Stat. 1860 Name of Statute: null
   PL: Pub.L. 108 - 173 101 Name of Law: Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)
  
PL: Pub.L. 108 - 173 101 Name of Law: Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)

0938-AT08 Proposed rulemaking 82 FR 56336 11/28/2017

  82 FR 56336 11/28/2017
No

No
No
The currently approved ROCIS table incorrectly sets out 7,588,143 hours of burden. This was mistakenly carried over from the 06/19/2015 Supporting Statement. The 10/27/2015 Supporting Statement correctly sets out 8,581,027 hours of burden, a difference of 992,884 hours. We are not proposing any changes to Supporting Statement sections 12.1. (Business Continuity Plans) for the private sector, 12.2. (Medicare Prescription Drug Benefit Program) for individuals/households, and 12.4. (State Eligibility Determinations) for states. However, in section 12.3. (Medicare Prescription Drug Benefit Program) we propose a number of private sector burden adjustments. We also propose to add requirements/burden in line with the proposed rule’s (CMS-4182-P, RIN 0938-AT08) CARA provisions in addition to new burden associated with the NPRM’s Access to Covered Part D Drugs; Preclusion List.”

$744
No
    No
    No
No
No
No
Uncollected
Mitch Bryman 410 786-5258 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
12/26/2017


© 2024 OMB.report | Privacy Policy